LDX improves subjective measures of executive function. The decrease in BADDS scores from baseline was significantly greater with LDX versus placebo for both (a) total BADDS (F=26.6, df=13, P<0.0002) and (b) each BADDS subscale (organization/activation for work, F=14.3, df=13, P=0.002; attention/concentration, F=31.7, df=13, P<0.0001; alertness/effort/processing speed, =12.3, df=13, P=0.004; managing affective interference, F=4.8, df=13, P=0.05; working memory/accessing recall, F=14.4, df=13, P=0.002). Error bars represent standard error.